Edgewood Management Has Lowered Cme Group (CME) Holding; 2 Analysts Bullish Merrimack Pharmaceuticals, Inc. (MACK)

May 23, 2018 - By Ann Lacey

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Logo

Among 6 analysts covering Merrimack Pharmaceuticals (NASDAQ:MACK), 2 have Buy rating, 0 Sell and 4 Hold. Therefore 33% are positive. Merrimack Pharmaceuticals had 11 analyst reports since August 12, 2015 according to SRatingsIntel. The firm has “Hold” rating by Robert W. Baird given on Monday, September 11. On Wednesday, August 12 the stock rating was reinitiated by Oppenheimer with “Outperform”. The firm has “Outperform” rating by Oppenheimer given on Tuesday, October 27. The stock of Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) has “Outperform” rating given on Wednesday, August 12 by Mizuho. The stock has “Buy” rating by Brean Capital on Tuesday, August 11. On Friday, August 19 the stock rating was initiated by BTIG Research with “Neutral”. The stock has “Neutral” rating by JP Morgan on Friday, October 7. The firm has “Neutral” rating by Robert W. Baird given on Friday, May 27. The company was maintained on Friday, October 13 by Robert W. Baird. The firm earned “Buy” rating on Wednesday, December 23 by Mizuho. See Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) latest ratings:

08/05/2018 Broker: Cowen & Co Rating: Hold

Edgewood Management Llc decreased Cme Group Inc (CME) stake by 4.04% reported in 2017Q4 SEC filing. Edgewood Management Llc sold 310,280 shares as Cme Group Inc (CME)’s stock rose 9.29%. The Edgewood Management Llc holds 7.37M shares with $1.08B value, down from 7.68M last quarter. Cme Group Inc now has $54.52 billion valuation. The stock decreased 0.47% or $0.75 during the last trading session, reaching $160.11. About 784,404 shares traded. CME Group Inc. (NASDAQ:CME) has risen 37.71% since May 23, 2017 and is uptrending. It has outperformed by 26.16% the S&P500.

The stock decreased 0.92% or $0.08 during the last trading session, reaching $8.63. About 44,180 shares traded. Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) has declined 61.33% since May 23, 2017 and is downtrending. It has underperformed by 72.88% the S&P500.

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the United States. The company has market cap of $115.15 million. The company's therapeutic oncology candidates in clinical development include MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive, advanced non-small cell lung cancer; and MM-141 that is in Phase II clinical trial for treating previously untreated metastatic pancreatic cancer patients who have high serum levels of free IGF-1. It has a 0.24 P/E ratio. The Company’s therapeutic oncology candidates also comprise MM-310 for treating solid tumors; and MM-151 that has completed a Phase I clinical trial for treating solid tumors.

Another recent and important Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) news was published by Seekingalpha.com which published an article titled: “Merrimack Pharmaceuticals’ (MACK) CEO Richard Peters on Q1 2018 Results – Earnings Call Transcript” on May 08, 2018.

Investors sentiment is 0 in Q4 2017. Its the same as in 2017Q3. It has no change, as 2 investors sold Merrimack Pharmaceuticals, Inc. shares while 0 reduced holdings. only 0 funds opened positions while 0 raised stakes. 27,550 shares or 99.05% less from 2.91 million shares in 2017Q3 were reported. Horrell Capital Mgmt accumulated 50 shares or 0% of the stock. Dekabank Deutsche Girozentrale has invested 0% in Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK).

More recent CME Group Inc. (NASDAQ:CME) news were published by: Prnewswire.com which released: “CME Group Inc. Announces Election of Class B-1 Directors” on May 23, 2018. Also Seekingalpha.com published the news titled: “CME: Great Business, But Grossly Overvalued” on May 08, 2018. Fool.com‘s news article titled: “CME Group (CME) Q1 2018 Earnings Conference Call Transcript” with publication date: April 27, 2018 was also an interesting one.

Since December 18, 2017, it had 0 insider purchases, and 10 sales for $9.68 million activity. The insider Piell Hilda Harris sold 3,299 shares worth $539,452. Pietrowicz John W. sold $1.14 million worth of stock. Sammann Derek sold $387,972 worth of stock. The insider Kometer Kevin sold 16,105 shares worth $2.61 million. Another trade for 2,325 shares valued at $354,051 was made by Tobin Jack J on Monday, December 18. Shares for $31,982 were sold by Pankau Ronald A. on Wednesday, February 14. 300 shares were sold by GEPSMAN MARTIN J, worth $49,287.

Investors sentiment increased to 1.15 in 2017 Q4. Its up 0.14, from 1.01 in 2017Q3. It increased, as 29 investors sold CME shares while 224 reduced holdings. 78 funds opened positions while 212 raised stakes. 265.76 million shares or 0.05% less from 265.89 million shares in 2017Q3 were reported. Profund Advsr Lc reported 0.06% in CME Group Inc. (NASDAQ:CME). Appleton Partners Incorporated Ma owns 0.24% invested in CME Group Inc. (NASDAQ:CME) for 10,739 shares. Loring Wolcott And Coolidge Fiduciary Advsr Ltd Liability Partnership Ma invested in 175 shares. Caprock Group Inc Inc, Idaho-based fund reported 4,875 shares. Horizon Kinetics Limited Liability Co accumulated 213,998 shares or 0.92% of the stock. Magnetar Ltd Llc holds 0.02% or 6,662 shares. Acadian Asset Mngmt Limited Liability Corp holds 0% of its portfolio in CME Group Inc. (NASDAQ:CME) for 532 shares. Virtus Invest Advisers Inc holds 0.09% of its portfolio in CME Group Inc. (NASDAQ:CME) for 15,358 shares. The Georgia-based Voya Investment Management Limited Liability Com has invested 0.04% in CME Group Inc. (NASDAQ:CME). Lombard Odier Asset Mgmt (Switzerland) Sa holds 0.02% or 1,400 shares in its portfolio. Sentry Investments owns 54,421 shares. Lombard Odier Asset Management (Europe) Ltd holds 0.04% of its portfolio in CME Group Inc. (NASDAQ:CME) for 3,999 shares. Piedmont Advisors Ltd Limited Liability Company has invested 0.21% in CME Group Inc. (NASDAQ:CME). Madison Invest Inc reported 124,887 shares. Glenview Fincl Bank Tru Dept owns 35,418 shares for 2.39% of their portfolio.

Edgewood Management Llc increased Celgene Corp (NASDAQ:CELG) stake by 976,596 shares to 11.53M valued at $1.20 billion in 2017Q4. It also upped Illumina Inc (NASDAQ:ILMN) stake by 42,683 shares and now owns 5.18 million shares. Spdr S&P 500 Etf Tr (SPY) was raised too.

Among 19 analysts covering CME Group (NASDAQ:CME), 11 have Buy rating, 1 Sell and 7 Hold. Therefore 58% are positive. CME Group had 64 analyst reports since August 3, 2015 according to SRatingsIntel. The rating was maintained by Jefferies on Tuesday, August 22 with “Buy”. JP Morgan downgraded CME Group Inc. (NASDAQ:CME) on Monday, November 14 to “Neutral” rating. The company was maintained on Thursday, June 1 by Keefe Bruyette & Woods. The firm earned “Buy” rating on Tuesday, January 26 by Deutsche Bank. The stock has “Buy” rating by Goldman Sachs on Wednesday, February 7. The stock of CME Group Inc. (NASDAQ:CME) earned “Equal Weight” rating by Barclays Capital on Tuesday, August 11. Barclays Capital maintained CME Group Inc. (NASDAQ:CME) on Friday, July 29 with “Equal-Weight” rating. As per Monday, October 16, the company rating was maintained by RBC Capital Markets. The stock of CME Group Inc. (NASDAQ:CME) has “Buy” rating given on Friday, July 29 by Deutsche Bank. On Friday, May 20 the stock rating was initiated by Sterne Agee CRT with “Neutral”.

CME Group Inc. (NASDAQ:CME) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: